SOLENO THERAPEUTICS INC Quarterly Debt-to-equity in % from Q3 2015 to Q4 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Soleno Therapeutics Inc quarterly Debt-to-equity history and growth rate from Q3 2015 to Q4 2024.
  • Soleno Therapeutics Inc Debt-to-equity for the quarter ending December 31, 2024 was 17.9 %, a 64.7% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q4 2024 17.9 -32.7 -64.7% Dec 31, 2024
Q3 2024 12.3 -177 -93.5% Sep 30, 2024
Q2 2024 18.6 -150 -89% Jun 30, 2024
Q1 2024 31.9 -105 -76.7% Mar 31, 2024
Q4 2023 50.5 -40.1 -44.3% Dec 31, 2023
Q3 2023 189 +105 +124% Sep 30, 2023
Q2 2023 168 +82.4 +96% Jun 30, 2023
Q1 2023 137 +52.5 +62.2% Mar 31, 2023
Q4 2022 90.7 +12.4 +15.9% Dec 31, 2022
Q3 2022 84.2 +21.3 +33.9% Sep 30, 2022
Q2 2022 85.8 +33.1 +62.6% Jun 30, 2022
Q1 2022 84.4 +39 +85.9% Mar 31, 2022
Q4 2021 78.3 +22.7 +40.7% Dec 31, 2021
Q3 2021 62.9 -8.86 -12.3% Sep 30, 2021
Q2 2021 52.8 -33.5 -38.8% Jun 30, 2021
Q1 2021 45.4 -105 -69.8% Mar 31, 2021
Q4 2020 55.6 -52.3 -48.4% Dec 31, 2020
Q3 2020 71.8 -3.25 -4.33% Sep 30, 2020
Q2 2020 86.3 +7.22 +9.13% Jun 30, 2020
Q1 2020 150 +78.3 +108% Mar 31, 2020
Q4 2019 108 +37.9 +54.1% Dec 31, 2019
Q3 2019 75 +2.61 +3.6% Sep 30, 2019
Q2 2019 79.1 +28.8 +57.4% Jun 30, 2019
Q1 2019 72.2 +40 +125% Mar 31, 2019
Q4 2018 70 +48.7 +228% Dec 31, 2018
Q3 2018 72.4 +57.2 +375% Sep 30, 2018
Q2 2018 50.2 Jun 30, 2018
Q1 2018 32.2 Mar 31, 2018
Q4 2017 21.3 Dec 31, 2017
Q3 2017 15.2 Sep 30, 2017
Q4 2015 -302 Dec 31, 2015
Q3 2015 -210 Sep 30, 2015
* An asterisk sign (*) next to the value indicates that the value is likely invalid.